Health AI Central
Share:
Peer-Reviewed Publication
Oncologist2026August 7, 2026Journal Article

Genomic Landscape and Therapeutic Implications of ALK Fusion-Positive Colorectal Cancer.

Xuanyi Li1, Faiza Yasin2, Dean C Pavlick3, Jeffrey S Ross3,4, Michael Cecchini1
1Yale Cancer Center, New Haven CT.
2Dana-Farber Cancer Institute, Boston MA.
3Foundation Medicine, Inc., Boston MA.
4Upstate Medical University, Syracuse, NY.
PubMed DOI

Abstract

BACKGROUND: Anaplastic lymphoma kinase (ALK) fusions are established oncogenic drivers and therapeutic targets in multiple malignancies, including non-small cell lung cancer but are rare in colorectal cancer (CRC). Although ALK fusions in CRC have been associated with sensitivity to ALK inhibitors, their broader genomic context remains incompletely defined. We aimed to characterize the prevalence,…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.